Farzin Haque
Stock Analyst at Jefferies
(1.21)
# 3,511
Out of 4,405 analysts
11
Total ratings
36.4%
Success rate
-3.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Farzin Haque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VOR Vor Biopharma | Initiated Coverage: Buy | $50 | $14.09 | +254.86% | 1 | Mar 29, 2026 | |
| RLMD Relmada Therapeutics | Initiated Coverage: Buy | $9 | $6.52 | +38.04% | 1 | Dec 21, 2025 | |
| VERA Vera Therapeutics | Maintained: Buy | $57 → $45 | $33.65 | +33.73% | 4 | Nov 26, 2025 | |
| RIGL Rigel Pharmaceuticals | Upgraded: Buy | $42 | $32.08 | +30.92% | 1 | Nov 5, 2025 | |
| NUVB Nuvation Bio | Initiated Coverage: Buy | $10 | $4.76 | +110.08% | 1 | Sep 29, 2025 | |
| HOWL Werewolf Therapeutics | Initiated Coverage: Buy | $4 | $0.3942 | +914.71% | 1 | Aug 4, 2025 | |
| PYXS Pyxis Oncology | Maintained: Buy | $10 → $6 | $1.67 | n/a | 2 | Mar 18, 2025 |
Vor Biopharma
Mar 29, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $14.09
Upside: +254.86%
Relmada Therapeutics
Dec 21, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $6.52
Upside: +38.04%
Vera Therapeutics
Nov 26, 2025
Maintained: Buy
Price Target: $57 → $45
Current: $33.65
Upside: +33.73%
Rigel Pharmaceuticals
Nov 5, 2025
Upgraded: Buy
Price Target: $42
Current: $32.08
Upside: +30.92%
Nuvation Bio
Sep 29, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $4.76
Upside: +110.08%
Werewolf Therapeutics
Aug 4, 2025
Initiated Coverage: Buy
Price Target: $4
Current: $0.3942
Upside: +914.71%
Pyxis Oncology
Mar 18, 2025
Maintained: Buy
Price Target: $10 → $6
Current: $1.67
Upside: n/a